Non–T-cell–depleted HLA haploidentical stem cell transplantation in advanced hematologic malignancies based on the feto-maternal michrochimerism

Non-T-cell-depleted HLA haploidentical stem cell transplantation based on feto-maternal microchimerism in pediatric patients with advanced malignancies

“…3,7 As summarized in Table 1, IPAs of the patients were detected in the peripheral blood of the mothers (cases 3-6, 8 and 9) and NIMA was detected in the peripheral blood of the donors (cases 2 and 10), suggesting immunologic tolerance to the recipient cells. IPA of two patients (cases 7 and 11) was undetectable in the peripheral blood of the donors.…”

“…1,2 Guided by the hypothesis that persistent maternal microchimerism indicates tolerance to fetally inherited paternal antigens (IPA) in children and that microchimerism among siblings with mismatched maternal antigens results in mutual tolerance to noninherited maternal antigens (NIMA), feto-maternal immunologic tolerance in allogeneic stem cell transplantation (SCT) has recently been investigated. [2][3][4][5][6] Based on this premise, we used non-T-cell-depleted (TCD) stem cells from haploidentical family donors for transplantation. We report here a total of 11 pediatric patients with advanced hematologic malignancies or solid tumors who underwent non-TCD haploidentical SCT.…”

Prophylactic and therapeutic treatment of graft-versus-host disease in Japan

“…Based on the hypothesis that feto-maternal immunological tolerance exists between the mother and fetus, studies of HLA-haploidentical transplantation from the mother, siblings or offspring that were mismatched for noninherited maternal antigens (NIMA) were performed in a small number of cases [98][99][100]. Ichinohe et al [101] analyzed the data of the JSHCT and demonstrated that incidences of grade II-IV acute GVHD and extensive chronic GVHD were 56 and 57 %, respectively, in patients who received HLA-haploidentical transplantation from NIMA-mismatched family members.…”

Successful non-T-cell-depleted nonmyeloablative hematopoietic stem cell transplantation (NST) from an HLA-haploidentical 2-loci-mismatched sibling in a heavily transfused patient with severe aplastic anemia based on the fetomaternal microchimerism

“…[5][6][7] Based on this hypothesis, it is feasible to perform non-T-cell-depleted (non-TCD) SCT between haploidentical family members and patients with refractory, high-risk hematological malignancies. 8 However, for nonmalignant diseases, no successful cases of NST from a haploidentical sibling donor have been reported. This patient was refractory to anabolic steroids, some immunosuppressive drugs, and antithymocyte globulin (ATG).…”